Valerio Therapeutics Launches InVimmune to Advance In Vivo Cell Therapy

May 4 2026-

Valerio Therapeutics has announced the launch of InVimmune, a new company focused on developing differentiated in vivo cell therapy approaches with potential applications across oncology, fibrosis, autoimmune diseases, and other indications. The new company represents an expansion of Valerio’s technology platforms into immune reprogramming and targeted delivery, with its first program focused on oncology, an area with significant unmet medical need.

InVimmune will leverage Valerio’s proprietary single-domain antibody platform together with targeted-delivery capabilities to develop novel therapeutic programs. Unlike traditional ex vivo cell therapy approaches, which require cells to be collected, engineered outside the body, and reinfused, in vivo cell therapy aims to reprogram or direct immune cells inside the patient’s body. This approach could potentially simplify treatment logistics, broaden patient access, and enable application across multiple disease areas if successfully translated into the clinic.

To support the first oncology program, Valerio has established a dedicated Oncology Scientific Advisory Board, chaired by Professor Eric Vivier. The board includes leading experts in immunology, oncology, and cell therapy, including Frederick Ramsdell, PhD, 2025 Nobel Prize in Physiology or Medicine laureate and Chair of the Scientific Advisory Board at Sonoma Biotherapeutics; Alan Korman, PhD, Chief Scientific Officer and Board Member at BlueSphere Bio; Matteo Iannacone, MD, PhD, Professor of Pathology and Head of the Dynamics of Immune Responses laboratory at the San Raffaele Scientific Institute and University in Milan; and François Romagné, former CSO of Innate Pharma and Professor of Immunotechnology.

In parallel, Olivier Demaria, PhD, will serve as Chief Scientific Officer of both Valerio and InVimmune and will also join InVimmune’s Oncology Scientific Advisory Board, helping ensure scientific continuity between the two organizations. Wael Jdey, PhD, will be promoted to Chief Technical Officer of Valerio.

The launch of InVimmune reflects growing industry interest in targeted in vivo immune engineering, a field that could reshape how cell therapies are developed and delivered. By combining targeted delivery, single-domain antibody technologies, and immune reprogramming, InVimmune aims to build a differentiated therapeutic platform that may eventually extend beyond oncology into fibrosis, autoimmune diseases, and other complex conditions.